MedTrace Logo

Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

NCT01039792 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2017-02-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the supplement Methyl B12 is effective in treating some of the symptoms of Autism.

Conditions

  • Autistic Disorder

Interventions

DRUG

Methyl B12

75 µg/Kg subcutaneously injected once every 3 days

DIETARY_SUPPLEMENT

Placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Robert L. Hendren, DO · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-10-31
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01039792 on ClinicalTrials.gov